1
00:00:02,520 --> 00:00:07,400
Speaker 1: Bloomberg Audio Studios, Podcasts, radio, news.

2
00:00:07,960 --> 00:00:10,880
Speaker 2: Business, Bloomberg Markets. I'm Scarlett Food. It's time now for

3
00:00:10,960 --> 00:00:14,160
Speaker 2: the stock of the hour, and we're focused on Teva Pharmaceuticals.

4
00:00:14,160 --> 00:00:16,880
Speaker 2: Those shares are rising after the drug maker reaffirmed its

5
00:00:16,880 --> 00:00:20,919
Speaker 2: full year revenue guidance, even after sales missed estimates for

6
00:00:21,000 --> 00:00:23,759
Speaker 2: the second quarter. For the quarter that ended, Teva is

7
00:00:23,800 --> 00:00:25,960
Speaker 2: gearing up to launch new products in the second half

8
00:00:26,000 --> 00:00:28,080
Speaker 2: of the year and looking at spinning off its active

9
00:00:28,240 --> 00:00:31,440
Speaker 2: ingredient business, which it hopes will work as catalysts. So

10
00:00:31,640 --> 00:00:34,360
Speaker 2: joining us live, I'm pleased to say, is the Teva CEO,

11
00:00:34,479 --> 00:00:37,440
Speaker 2: Richard Francis, and of course Bloomberg Open Interest co hosts

12
00:00:37,640 --> 00:00:41,000
Speaker 2: Katie Greifeld here with us as well. Richard, thank you

13
00:00:41,000 --> 00:00:43,120
Speaker 2: so much for speaking with us. I want to start

14
00:00:43,159 --> 00:00:47,480
Speaker 2: with the backdrop that you are operating against, which is tariffs,

15
00:00:47,520 --> 00:00:49,960
Speaker 2: and how that affects you the US and you kicked

16
00:00:49,960 --> 00:00:53,880
Speaker 2: off this week agreeing to fifteen percent tariffs on pharmaceuticals.

17
00:00:54,280 --> 00:00:56,560
Speaker 2: How does that affect your business, particularly here.

18
00:00:56,440 --> 00:00:57,000
Speaker 3: In the US.

19
00:00:58,480 --> 00:01:00,520
Speaker 4: Well, firstly, thank you Scott Kate for having me. I

20
00:01:00,640 --> 00:01:03,120
Speaker 4: do appreciate the time. So when it comes to tariffs, yes,

21
00:01:03,160 --> 00:01:07,080
Speaker 4: that is hot, hot topic and how it impacts us.

22
00:01:07,120 --> 00:01:08,640
Speaker 4: A couple of things I'd say is, firstly, we're not

23
00:01:08,800 --> 00:01:11,760
Speaker 4: super clear on exactly the detail of what's happened in

24
00:01:11,800 --> 00:01:14,480
Speaker 4: Europe and whether generics are included or whether they're not.

25
00:01:14,920 --> 00:01:16,880
Speaker 3: I would like to say the exposure to China.

26
00:01:17,160 --> 00:01:19,200
Speaker 4: We don't have an exposure to China, and we are

27
00:01:19,360 --> 00:01:22,240
Speaker 4: very limited exposure to India because obviously you saw the

28
00:01:22,280 --> 00:01:23,800
Speaker 4: tariff's beIN announced this morning.

29
00:01:24,400 --> 00:01:26,119
Speaker 3: But I think the reason why I.

30
00:01:26,080 --> 00:01:28,240
Speaker 4: Thought in a good position is our supply chain and

31
00:01:28,280 --> 00:01:30,920
Speaker 4: how it sets up. So we have eight manufacturing sites

32
00:01:30,959 --> 00:01:34,160
Speaker 4: in the US already, and our major product, which I'm

33
00:01:34,160 --> 00:01:37,000
Speaker 4: sure we'll talk about, oesteto, which grow twenty two percent

34
00:01:37,000 --> 00:01:40,840
Speaker 4: of the US, is manufactured in Florida. So I think

35
00:01:40,840 --> 00:01:43,039
Speaker 4: from a point of view a supply chain, we're in

36
00:01:43,080 --> 00:01:45,120
Speaker 4: a good position. But what we do need to have

37
00:01:45,240 --> 00:01:48,640
Speaker 4: is clarity on what these tariffs mean in Europe and

38
00:01:48,680 --> 00:01:51,760
Speaker 4: what they mean in other parts of the world, and

39
00:01:51,800 --> 00:01:53,880
Speaker 4: the detail of that, because there has been some rumors

40
00:01:53,880 --> 00:01:55,000
Speaker 4: that generics.

41
00:01:54,520 --> 00:01:57,280
Speaker 3: May be excluded or not until we'll have to wait

42
00:01:57,320 --> 00:01:57,600
Speaker 3: and see.

43
00:01:57,720 --> 00:02:00,440
Speaker 2: Yeah, no, you're working in a fog of uncertainty. Get that,

44
00:02:00,480 --> 00:02:03,000
Speaker 2: and I'm just curious whether you've had conversations with the

45
00:02:03,000 --> 00:02:05,440
Speaker 2: White House or surroguits of the White House on these

46
00:02:05,440 --> 00:02:06,280
Speaker 2: specific issues.

47
00:02:07,280 --> 00:02:07,960
Speaker 3: Well, we've been.

48
00:02:07,800 --> 00:02:09,880
Speaker 4: Working with them on two three two and make it,

49
00:02:09,919 --> 00:02:12,600
Speaker 4: helping them sort of work through what is the complexity

50
00:02:12,639 --> 00:02:15,720
Speaker 4: of the pharmaceutical market, the supply change as well as

51
00:02:15,919 --> 00:02:18,280
Speaker 4: on the innovative side and on the generic side.

52
00:02:18,400 --> 00:02:20,520
Speaker 3: But with regard to these tariffs that.

53
00:02:20,400 --> 00:02:23,240
Speaker 4: Have just recently announced, we don't have any clarity yet

54
00:02:23,400 --> 00:02:23,959
Speaker 4: on the detail.

55
00:02:24,000 --> 00:02:25,680
Speaker 3: What I would say is because of.

56
00:02:25,600 --> 00:02:27,720
Speaker 4: What I said about our supply chain and our footprint

57
00:02:27,760 --> 00:02:29,880
Speaker 4: in the US as well as we've been working the

58
00:02:29,919 --> 00:02:34,000
Speaker 4: last few months on mitigating plans.

59
00:02:33,639 --> 00:02:36,360
Speaker 3: As to whatever may happen. Now let's see the detail.

60
00:02:36,639 --> 00:02:39,360
Speaker 4: But it's something where I think we already would have

61
00:02:39,440 --> 00:02:42,760
Speaker 4: plans in place to at least mitigate some of this.

62
00:02:43,320 --> 00:02:45,440
Speaker 1: I hear what you're saying, Richard, that there's a lot

63
00:02:45,480 --> 00:02:47,880
Speaker 1: of details that we would all like to have, especially

64
00:02:47,919 --> 00:02:51,760
Speaker 1: you where you're sitting as the CEO of a pharmaceutical business.

65
00:02:51,760 --> 00:02:54,280
Speaker 1: But you said in May that you would have to

66
00:02:54,360 --> 00:02:58,200
Speaker 1: raise drug prices if President Trump imposed those pharma tariffs.

67
00:02:58,240 --> 00:03:00,919
Speaker 1: So now that we have at least some details. When

68
00:03:00,960 --> 00:03:03,480
Speaker 1: it comes to the US and the EU, is that

69
00:03:03,800 --> 00:03:06,200
Speaker 1: still the plan? Is that a lever that you planned

70
00:03:06,200 --> 00:03:06,560
Speaker 1: a pull?

71
00:03:07,760 --> 00:03:09,840
Speaker 4: Well, I g when you think about the two businesses

72
00:03:09,880 --> 00:03:11,880
Speaker 4: we have, we have the innovative business and we have

73
00:03:11,919 --> 00:03:15,480
Speaker 4: the generics. On the innovative business, we won't increased prices

74
00:03:15,520 --> 00:03:17,800
Speaker 4: because the way the system set up, we can't.

75
00:03:18,480 --> 00:03:19,520
Speaker 3: So that's just the fact.

76
00:03:19,520 --> 00:03:22,000
Speaker 4: But as I said, our major products actually made in

77
00:03:22,040 --> 00:03:25,120
Speaker 4: the United States, so tariffs are not actually relevant to that,

78
00:03:25,840 --> 00:03:27,560
Speaker 4: which is good for US. I think when it comes

79
00:03:27,600 --> 00:03:30,639
Speaker 4: to Generics, is a very competitive market and you can

80
00:03:31,080 --> 00:03:33,480
Speaker 4: you can only raise prices when you have a new contract,

81
00:03:33,520 --> 00:03:36,360
Speaker 4: and in that position, we would instill a free market.

82
00:03:36,400 --> 00:03:39,000
Speaker 4: So it depends what our competitors do. So I think

83
00:03:39,280 --> 00:03:42,080
Speaker 4: the ability for prices to change will depend on the

84
00:03:42,120 --> 00:03:44,720
Speaker 4: competitive environment and how some of our competitors move. So

85
00:03:44,760 --> 00:03:47,080
Speaker 4: I think will they go up? I think we'll have

86
00:03:47,120 --> 00:03:50,200
Speaker 4: to wait and see. There is the potential that they could.

87
00:03:50,520 --> 00:03:53,400
Speaker 4: But I would argue that you know, in the United States,

88
00:03:53,520 --> 00:03:56,120
Speaker 4: one in fifteen scripts is a tap a script. So

89
00:03:56,120 --> 00:03:58,640
Speaker 4: we are a major supplier of the healthcare system in

90
00:03:58,640 --> 00:04:01,760
Speaker 4: the United States, and we've been community into the administration

91
00:04:02,080 --> 00:04:04,760
Speaker 4: who are very aware of this, and I would say sympathetic.

92
00:04:04,800 --> 00:04:06,480
Speaker 4: They want to make sure there is a good supply

93
00:04:06,840 --> 00:04:09,360
Speaker 4: of medicines to the United States, and so I think

94
00:04:09,400 --> 00:04:12,400
Speaker 4: as that all plays together, we'll understand actually how tarifs

95
00:04:12,720 --> 00:04:15,960
Speaker 4: do fall on the generics and or if they do

96
00:04:16,160 --> 00:04:18,040
Speaker 4: or if they don't. But I think that's how it's

97
00:04:18,040 --> 00:04:19,920
Speaker 4: separated up is we have the innovative where we can't

98
00:04:20,000 --> 00:04:22,760
Speaker 4: raise prices. Theoretically you can in generics, right, but it

99
00:04:22,880 --> 00:04:24,680
Speaker 4: is a competitive environment.

100
00:04:25,080 --> 00:04:27,240
Speaker 1: I appreciate the context there. I want to talk about

101
00:04:27,560 --> 00:04:30,359
Speaker 1: another issue that we are also searching for details on,

102
00:04:30,400 --> 00:04:33,680
Speaker 1: and that is Most Favored Nation drug pricing. That is

103
00:04:33,720 --> 00:04:36,880
Speaker 1: a proposal that President Trump has floated. We've been talking

104
00:04:36,920 --> 00:04:39,880
Speaker 1: about your generics business, but when it comes to your

105
00:04:39,920 --> 00:04:44,560
Speaker 1: branded franchise, how might MFN affect that and are you

106
00:04:44,640 --> 00:04:46,200
Speaker 1: putting any plans in place there?

107
00:04:47,360 --> 00:04:51,080
Speaker 4: Well, actually, we're in a really unique position here, Katie.

108
00:04:51,120 --> 00:04:53,200
Speaker 3: So I don't think most people are sit in my

109
00:04:53,320 --> 00:04:54,679
Speaker 3: seat will.

110
00:04:54,480 --> 00:04:57,840
Speaker 4: Answer it this way. Is because our innovative portfolio is

111
00:04:57,880 --> 00:05:02,640
Speaker 4: so young. I mean, it's twenty seven cent growth and

112
00:05:03,040 --> 00:05:05,599
Speaker 4: is closing on two point nine billion dollars of revenue.

113
00:05:05,800 --> 00:05:09,720
Speaker 4: And this is a Stato a jovi and you said it,

114
00:05:09,760 --> 00:05:13,080
Speaker 4: but apart from a Jovi, these are basically sold in

115
00:05:13,080 --> 00:05:15,440
Speaker 4: the United States. We haven't gone global yet and so

116
00:05:15,600 --> 00:05:18,240
Speaker 4: because of that, the most favored nation pricing I think one,

117
00:05:18,279 --> 00:05:20,200
Speaker 4: we need to see what it says and when it's

118
00:05:20,200 --> 00:05:20,880
Speaker 4: going to be.

119
00:05:20,720 --> 00:05:21,400
Speaker 3: Put in place.

120
00:05:21,839 --> 00:05:24,760
Speaker 4: But we're not a mature by a farmer company yet

121
00:05:24,880 --> 00:05:28,080
Speaker 4: where we have that geographical footprint of our innovative business.

122
00:05:28,320 --> 00:05:31,839
Speaker 4: So that gives us, I think, time to think about

123
00:05:31,839 --> 00:05:34,200
Speaker 4: what we do, to think about where we launch our products,

124
00:05:34,360 --> 00:05:37,160
Speaker 4: and to think about the pricing. But right now, Oestio

125
00:05:37,160 --> 00:05:39,480
Speaker 4: and your studia are pretty much sold in the United States.

126
00:05:40,839 --> 00:05:44,200
Speaker 4: A Jovi is sped across Europe and international markets, so

127
00:05:44,240 --> 00:05:47,440
Speaker 4: that's a very limited footprint compared to many other biofarmer companies.

128
00:05:48,240 --> 00:05:50,320
Speaker 4: What I would say is it's important to understand what

129
00:05:50,360 --> 00:05:52,920
Speaker 4: the most favored nation look like. Because another thing I'd

130
00:05:52,960 --> 00:05:55,760
Speaker 4: say is when you look at the actual net price

131
00:05:55,760 --> 00:05:59,040
Speaker 4: of products in the United States, on many cases, because

132
00:05:59,080 --> 00:06:03,280
Speaker 4: of what has happened with the PBMs over time, the

133
00:06:03,320 --> 00:06:06,240
Speaker 4: net price versus the price in Europe, there's not as

134
00:06:06,240 --> 00:06:11,159
Speaker 4: big a differentiation that's differential as you'd imagine on many.

135
00:06:11,040 --> 00:06:13,279
Speaker 3: Drugs, so let's wait and see how it plays up.

136
00:06:13,279 --> 00:06:14,880
Speaker 4: But I think we're in a strong position as TeV

137
00:06:15,320 --> 00:06:18,680
Speaker 4: and that's important because our innovative portfolio is growing so

138
00:06:18,960 --> 00:06:20,520
Speaker 4: well at twenty seven percent.

139
00:06:20,960 --> 00:06:22,920
Speaker 1: And Richard, we have less than a minute left here.

140
00:06:22,960 --> 00:06:25,720
Speaker 1: But Scarlett alluded to this in the intro that there's

141
00:06:25,760 --> 00:06:29,040
Speaker 1: a lot of interest in the Tappy business over at Teva.

142
00:06:29,120 --> 00:06:30,920
Speaker 1: Have you found a buyer yet?

143
00:06:32,200 --> 00:06:35,039
Speaker 4: So we've been in active discussions and we are in

144
00:06:35,080 --> 00:06:37,640
Speaker 4: active discussions, which is why I'll probably keep this quite

145
00:06:38,040 --> 00:06:41,480
Speaker 4: short and we'll have an announcement on this at the

146
00:06:41,560 --> 00:06:44,200
Speaker 4: end of Q three. What we are doing is taking

147
00:06:44,240 --> 00:06:46,599
Speaker 4: the time to make sure whatever we do, we really

148
00:06:46,600 --> 00:06:49,560
Speaker 4: bring value to our shelders, which is the prime responsibility

149
00:06:49,600 --> 00:06:51,920
Speaker 4: I have is to make sure we create a long term,

150
00:06:51,920 --> 00:06:54,720
Speaker 4: sustainable company that creates shelder value.

151
00:06:54,960 --> 00:06:57,280
Speaker 2: Richard Francis, you've just earned yourself an invitation to come

152
00:06:57,320 --> 00:06:59,839
Speaker 2: back by the end of the third quarter with that announcement.

153
00:07:00,080 --> 00:07:02,960
Speaker 2: Thank you so much for joining us today, Pharmaceutical CEO,

154
00:07:03,040 --> 00:07:04,960
Speaker 2: Richard Francis, And of course Katie where I fell at

155
00:07:04,960 --> 00:07:06,440
Speaker 2: Bloomberg Open Interests co host